KRTX stock forecast
Our latest prediction for Karuna Therapeutics, Inc.'s stock price was made on the July 2, 2019 when the stock price was at 21.70$.
In the short term (2weeks), KRTX's stock price should outperform the market by 5.54%. During that period the price should oscillate between -2.54% and +4.46%.
In the medium term (3months), KRTX's stock price should outperform the market by 9.03%. During that period the price should oscillate between -5.34% and +12.33%.Get email alerts
About Karuna Therapeutics, Inc.
Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company develops treatments for people afflicted with schizophrenia. Karuna Therapeutics was founded in July 2009 by Andrew Miller, Eric Elenko and Peter Jeffrey Conn and is headquartered in Boston, MA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -3.24$ per share.
The book value per share is 3.75$
Three months stock forecastJuly 2, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|